期刊文献+

三联法治疗幽门螺杆菌性溃疡的临床分析 被引量:1

下载PDF
导出
摘要 目的探讨兰索拉唑、左氧氟沙星、甲硝唑三联1周疗法根除幽门螺杆菌(Hp)的疗效及安全性。方法选择56例符合条件的Hp阳性慢性胃炎和消化性溃疡患者,随机分成两组:治疗组采用兰索拉唑(30mg,2次/d)加左氧氟沙星(0.2g,2次/d)加甲硝唑(0.4g,2次/d),治疗7d;溃疡患者继续用兰索拉唑(30mg,1次/d),3周;对照组兰索拉唑(30mg,2次/d)加左氧氟沙星(0.2g,2次/d)加克拉霉紊(0.5g,2次/d),治疗7d;溃疡患者继续用兰索拉唑(30mg,1次/a),3周;疗程结束4周后复查,观察根除率,不良反应发生率等。结果治疗组和对照组的根除率、不良反应发生率分别为92.9%、7.1%和89.3%、14.3%,两组差异无显著性(P>0.05)。结论兰索拉唑、左氧氟沙星、甲硝唑三联1周疗法根除幽门螺杆菌可达90%,并且费用低,不良反应小,值得临床推广。
出处 《中国现代药物应用》 2009年第11期151-152,共2页 Chinese Journal of Modern Drug Application
  • 相关文献

参考文献4

二级参考文献14

  • 1王鋆,张钧.药物经济学成本-效果分析[J].药学实践杂志,1995,13(4):193-197. 被引量:462
  • 2Bazzili F, Zagari R M, Fossi S, et al. Short-term, low dose triple therapy for eradication of Helicobacter pylori. Eur J Gatroenterol Hepatal, 1994,6 : 773.
  • 3Dent JC,McNulty.CAM,Uff JC,et al.Spiral organisms in the gastric antrum. Lancet,1987;2(8550):96-97.
  • 4Heilmann KL,Borchard F.Gastriris due to spiral shaped bacteria other than Helicobacter pylori:Clinic,histological, and ultrastructural findings.Gut,1991,32(2):137-1405.
  • 5彭杰青.胃的解剖结构和生理功能[A].同济医科大学病理教研室与中山医科大学病理教研室编著.外科病理学(上册)第2版[C].武汉:湖北科学技术出版社,1999.94.
  • 6Ling TK,Cheng AF,Sung JJ,et al.An increase in Helicobacter pylori strains resistant to metronidazole: a five-year study[].Helicobacter.1996
  • 7Vakil N,Hahn B,McSorley D.Clarithromycin-resistant Helicobacter pylori in patients with duodenal ulcer in the United States[].The American journal of Gastroenterology.1998
  • 8薛冬.成本-效果分析在3种心绞痛治疗方案中的应用[J].中国药房,1997,8(6):270-271. 被引量:60
  • 9郑鹏远,唐芙爱,华杰松,段芳龄.幽门螺杆菌二种形态的研究[J].中华消化杂志,1999,19(4):230-232. 被引量:18
  • 10胡伏莲.重视幽门螺杆菌耐药株的研究[J].中华医学杂志,2000,80(11):805-806. 被引量:12

共引文献217

同被引文献10

  • 1陈东燕,孙艳荪,乔珊,吴子刚.CYP2C19基因多态性对幽门螺杆菌感染酸相关性疾病治愈率的影响[J].实用医学杂志,2006,22(19):2324-2326. 被引量:7
  • 2储楠楠,陈伟力,徐红蓉,周密,李雪宁.LC-MS/MS法测定人血浆中兰索拉唑及其代谢产物的浓度[J].药物分析杂志,2006,26(1):35-39. 被引量:4
  • 3Kato S, Fujimura S. Primary antimicrobial resistance of Helico bacter pylori in children during the past 9 Years[J]. Am J Med Sci,2010,52(2) : 187-190.
  • 4Murakami K, Okimoto T, Kodama M, et al. Evaluation of three different proton pump inhibitors with amoxicillin and metronidazole in retreatment for Helicobacter pylori infection[J]. J Dig Dis,2007,8(4):211- 215.
  • 5Pearce RE, Rodrigues AD,Goldstein J A, et a l. Identification of the human P450 enzymes involved in lansoprazole metabolism [J]. J Pharmacol Exp Ther, 1996,277(2):805-816.
  • 6Saito M, Yasui Furukori N, Uno T, et al, Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes[J].Br J Pharmacol,2005,59(3) : 302- 309.
  • 7Roedler R, Neuhauser MM, Penzak SR. Does metronidazole interact with CYP3A substrates by inhibiting their metabolism lhrough this metabolic pathway? Or should other mechanisms be considered[J].? Ann Pharmacother,2007,41 (4) : 653-658.
  • 8Kita T, Sakaeda T, Baba T, et al. Different contribution ot CYP2C19 in the in vitro metabolism of three proton pump inhibitors[J]. Biol Pharm Bull, 2003,26 (3) : 386-3911.
  • 9Jorden RA. Implications of antiretroviral therapy in oral medicine-a review of literature[J]. Schweiz Monatsscbr Zahnmed. 2007,117(12):1210 -1216.
  • 10李茜,邓俊刚,乔建,黎维勇.兰索拉唑片相对生物利用度与生物等效性研究[J].医药导报,2009,28(2):165-167. 被引量:5

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部